A $22 Billion Milestone and the Global Access Migration
Financial analysts at J.P. Morgan estimate that the addressable market for glucagon-like peptide-1 (GLP-1) receptor agonists across China, India, and Brazil will expand at a robust compound annual growth rate of 15% through 2035. Historically treated as premium lifestyle pharmaceuticals largely restricted to high-income patients in the United States and Western Europe, celebrated drugs such as Novo Nordisk's Ozempic and Wegovy, alongside Eli Lilly's Mounjaro and Zepbound, are steadily pivoting toward the world's most populous emerging economies.
This geographic broadening is fueled by an alarming epidemiological transition underway across developing societies. Today, China and India accommodate the planet's largest diagnosed diabetes populations, accounting for more than 25% and 15% of total worldwide cases, respectively. Concurrently, Brazil confronts an adult diabetes incidence exceeding 12%, compounding risks of severe cardiovascular comorbidities across diverse demographics.
GLP-1 is transitioning from a developed-market growth theme to a broader global access story as affordability improves.















